Biotron Company Description

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia.

The company’s lead antiviral drug is BIT225 that is in Phase 2 clinical trial for the treatment of HIV-1, as well as to treat hepatitis C virus infections; and BIT-HBV001 to treat hepatitis B virus and hepatitis delta virus.

It also develops preclinical drugs for viral diseases, such as dengue, zika, and influenza virus. The company was incorporated in 1999 and is based in Sydney, Australia.

Biotron Limited

Country	Australia
Founded	1999
Industry	Biotechnology
Sector	Healthcare
Employees	3
CEO	Michelle Miller

Contact Details

Address: 66 Hunter Street Sydney, NSW 2000 Australia
Phone	61 2 9300 3344
Website	biotron.com.au

Stock Details

Ticker Symbol	BIT
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU000000BIT4
SIC Code	2836

Key Executives

Name	Position
Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D.	MD and Executive Director
Marcelo Mora ACIS, B.Bus Aasa	Company Secretary